Peptide Synthesis Building Blocks: Fmoc-Orn(Boc)-OH Explained
In the intricate field of peptide synthesis, the selection of high-quality building blocks is paramount. Among these, protected amino acids play a crucial role in ensuring the correct assembly of peptide chains. One such vital component is N-alpha-Fmoc-Ndelta-Boc-L-ornithine (CAS 109425-55-0), a derivative of the amino acid ornithine that offers specific advantages for researchers and chemical manufacturers.
N-alpha-Fmoc-Ndelta-Boc-L-ornithine is characterized by two protecting groups: the Fmoc (9-fluorenylmethoxycarbonyl) group on the N-alpha position and the Boc (tert-butoxycarbonyl) group on the N-delta position. These protecting groups are essential for controlled peptide synthesis, particularly in the widely adopted Fmoc solid-phase peptide synthesis (SPPS) methodology. The Fmoc group can be selectively removed under mild basic conditions, allowing for the stepwise addition of amino acids, while the Boc group provides protection to the side chain amine until it is no longer needed or is removed during a specific deprotection step.
The incorporation of ornithine, a non-proteinogenic amino acid, into peptides can introduce unique structural and functional properties. This is particularly useful when designing cyclic peptides, where the side chain amine of ornithine can be utilized to form an amide bond, creating a constrained cyclic structure. These cyclic peptides often exhibit enhanced stability, improved pharmacokinetic profiles, and novel biological activities, making them attractive candidates for drug development. For example, understanding how to buy Fmoc-Orn(Boc)-OH is a critical step for researchers aiming to synthesize such complex molecules.
The chemical properties of N-alpha-Fmoc-Ndelta-Boc-L-ornithine, such as its melting point (111-115°C) and recommended storage temperature (2-8°C), are important considerations for handling and maintaining its integrity. Sourcing this material from a reputable manufacturer or supplier in China like NINGBO INNO PHARMCHEM CO.,LTD. ensures that researchers receive a product of consistent quality and purity, which is vital for the success of their experiments. When looking to purchase this reagent, understanding its specifications and the reliability of the supplier is key.
The application of N-alpha-Fmoc-Ndelta-Boc-L-ornithine extends beyond basic peptide synthesis. It is also a valuable tool in the development of diagnostic reagents and in various life science research applications. The ability to precisely introduce ornithine residues allows scientists to explore new peptide architectures and functionalities, potentially leading to breakthroughs in therapeutic areas. For those seeking to procure this essential compound, investigating the price and availability from established chemical suppliers is a strategic move. Many organizations are actively looking for a dependable Fmoc amino acid derivative supplier to support their ongoing research and development efforts.
In conclusion, N-alpha-Fmoc-Ndelta-Boc-L-ornithine is an indispensable building block for advanced peptide synthesis. Its unique structure and the presence of orthogonal protecting groups make it ideal for creating complex peptide structures. Researchers and developers seeking to obtain this high-purity reagent should prioritize sourcing from established manufacturers and suppliers who can guarantee quality and consistent availability, ensuring the efficiency and success of their scientific endeavors.
Perspectives & Insights
Nano Explorer 01
“The incorporation of ornithine, a non-proteinogenic amino acid, into peptides can introduce unique structural and functional properties.”
Data Catalyst One
“This is particularly useful when designing cyclic peptides, where the side chain amine of ornithine can be utilized to form an amide bond, creating a constrained cyclic structure.”
Chem Thinker Labs
“These cyclic peptides often exhibit enhanced stability, improved pharmacokinetic profiles, and novel biological activities, making them attractive candidates for drug development.”